3 "Strong Buy" Healthcare Stocks Under $5 That Could Double (Or More)
Quest Scores US Nod For Covid-19 Test Pooling; Speeding Up Response Times
An infectious disease expert explains the results from Moderna's latest vaccine trials
Study: Five-year review of all alzheimer’s drugs in development shows reason for optimism
Oppenheimer: These 2 "Strong Buy" Stocks Are Poised to Surge by Over 80%
Coronavirus pharma news roundup – 17/07/20
Orexo launches digital therapies for depression, alcohol misuse early in US
Some decontamination processes damage N95 face masks
3 "Strong Buy" Penny Stocks That Could Rally to $10 (Or More)
AstraZeneca Pops Ahead of Covid-19 Vaccine Data Report Due July 20
MRNA Stock Price Nears 52-Week Highs On COVID-19 Vaccine Results
BioNTech (BNTX): Fast Track Designation Does Not Justify Current Valuation, Says J.P. Morgan
Common FDA-approved drug may effectively neutralize virus that causes COVID-19
Merck CEO Expresses Concern About Rapid Covid-19 Vaccine Development
Experts urge transparency, advisory committee review for Covid-19 vaccines
Becton, Dickinson Score Fed Contract For Covid-19 Rapid Test Systems
Moderna Soars 16% As Covid-19 Vaccine Shows Strong Immune Response
FDA panel votes in favor of approving GSK’s multiple myeloma drug
Equillium (EQ) Stock Price Target Gets a Big Boost; Here's What You Need to Know
Akebia Initiates Vadadustat Study In Covid-19 Patients
Biogen, Eisai Start New Phase 3 Trial For Pre-clinical Alzheimer's Disease
Aldeyra Spikes 10% In Pre-Market On New Perceptive Stake
Medicago and Dynavax
A top analyst turns the spotlight on Moderna, fueling a fast-and-furious Street race over the future of mRNA
Pfizer, BioNTech Score Fast Track Status For Covid-19 Vaccine Candidates
Futures Jump Above 3,200 On Vaccine Optimism, Merger Monday
What US medical supply chain can learn from the fashion industry
Two years after a ‘positive’ result tanked their stock, Ovid's Jeremy Levin wins a partner for the PhIII journey
ElectroCore Pops 160% On FDA Nod For Covid-19 Asthma Device
Could pressure for COVID-19 drugs lead the FDA to lower its standards?